GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genexine Inc (XKRX:095700) » Definitions » Cyclically Adjusted Book per Share

Genexine (XKRX:095700) Cyclically Adjusted Book per Share : ₩9,781.68 (As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Genexine Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Genexine's adjusted book value per share for the three months ended in Mar. 2024 was ₩6,949.760. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ₩9,781.68 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Genexine's average Cyclically Adjusted Book Growth Rate was 6.80% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 17.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Genexine was 20.70% per year. The lowest was 17.30% per year. And the median was 19.00% per year.

As of today (2024-06-09), Genexine's current stock price is ₩7310.00. Genexine's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was ₩9,781.68. Genexine's Cyclically Adjusted PB Ratio of today is 0.75.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Genexine was 23.61. The lowest was 0.72. And the median was 5.76.


Genexine Cyclically Adjusted Book per Share Historical Data

The historical data trend for Genexine's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genexine Cyclically Adjusted Book per Share Chart

Genexine Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,080.08 6,004.09 7,753.88 8,922.94 9,682.00

Genexine Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9,160.21 9,327.02 9,590.48 9,682.00 9,781.68

Competitive Comparison of Genexine's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Genexine's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genexine's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genexine's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Genexine's Cyclically Adjusted PB Ratio falls into.



Genexine Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Genexine's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=6949.76/118.8477*118.8477
=6,949.760

Current CPI (Mar. 2024) = 118.8477.

Genexine Quarterly Data

Book Value per Share CPI Adj_Book
201406 2,585.030 99.353 3,092.256
201409 2,676.245 99.608 3,193.173
201412 4,885.077 99.098 5,858.647
201503 4,903.461 99.720 5,844.014
201506 5,078.416 100.050 6,032.564
201509 4,614.120 100.110 5,477.750
201512 5,430.685 100.220 6,440.076
201603 5,124.114 100.560 6,055.978
201606 4,789.119 100.790 5,647.145
201609 7,042.022 101.460 8,248.848
201612 5,221.380 101.560 6,110.171
201703 6,478.383 102.850 7,486.057
201706 6,285.032 102.610 7,279.618
201709 6,137.278 103.490 7,048.037
201712 4,078.227 102.990 4,706.165
201803 3,880.521 104.100 4,430.269
201806 10,784.215 104.130 12,308.452
201809 10,596.302 105.650 11,919.982
201812 11,233.459 104.350 12,794.162
201903 12,095.475 104.490 13,757.483
201906 11,430.411 104.880 12,952.689
201909 10,104.441 105.200 11,415.300
201912 8,977.288 105.120 10,149.639
202003 8,405.499 105.540 9,465.361
202006 10,785.714 104.870 12,223.298
202009 14,663.523 106.200 16,409.849
202012 15,580.375 105.765 17,507.538
202103 16,754.269 107.357 18,547.488
202106 20,526.495 107.579 22,676.691
202109 19,126.427 108.759 20,900.594
202112 14,861.323 109.676 16,104.048
202203 11,412.052 111.806 12,130.821
202206 10,590.185 114.083 11,032.506
202209 9,507.779 114.831 9,840.328
202212 8,340.573 115.200 8,604.654
202303 8,367.923 116.550 8,532.920
202306 7,736.315 117.140 7,849.104
202309 7,103.507 119.111 7,087.792
202312 7,156.170 118.848 7,156.170
202403 6,949.760 118.848 6,949.760

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Genexine  (XKRX:095700) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Genexine's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=7310.00/9781.68
=0.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Genexine was 23.61. The lowest was 0.72. And the median was 5.76.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Genexine Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Genexine's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Genexine (XKRX:095700) Business Description

Industry
Traded in Other Exchanges
N/A
Address
700 Daewangpangyo-ro, Gyeonggi-do, Korea Bio Park Building B, Bundang-gu, Seongnam-si, KOR, 13488
Genexine Inc is a clinical-stage biotechnology company. It is focused on the development and commercialization of immunotherapeutics and next-generation long-acting biologics. Its primary technologies are Therapeutic DNA vaccine technology and Hyfc platform. The company's product pipeline includes products such as GX-H9, GX-E2, GX-G3, GX-G6, and Papitrol-188 among others.

Genexine (XKRX:095700) Headlines

No Headlines